

Laurus Labs Limited  
Corporate Office  
2<sup>nd</sup> Floor, Serene Chambers, Road No. 7  
Banjara Hills, Hyderabad - 500034, India  
T +91 40 39804333 / 2342 0500 / 501  
F +91 40 3980 4320



Hyderabad,  
April 17, 2017

To  The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> Floor, Dalal Street Mumbai – 400001  <b>Code: 540222</b>	To  The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051  <b>Code: LAURUSLABS</b>
--	---

Dear Sirs,

**Sub: Investor Grievance Report for the Quarter ended March 31, 2017**


Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish hereunder the Statement of Investor Complaints for the Quarter ended March 31, 2017.


Sl.No.	Particulars	No. of Investor Complaints
(i)	Pending at the beginning of the Quarter	Nil
(ii)	Received during the Quarter	89
(iii)	Disposed-off during the Quarter	89
(iv)	Pending un-resolved at the end of the Quarter	Nil

This is for your information and records.

Thanking you,

Yours sincerely,  
For Laurus Labs Limited

  
G. Venkateswar Reddy  
Company Secretary



CIN: L24230AP2905PLC0847518

Registered Office : Plot No:21, J N Pharma City, Parawada, Visakhapatnam - 531021, India CIN : U24239AP2905PLC0847518  
T +91 891 3061222 F +91 891 3061270 E info@lauruslabs.com W lauruslabs.com

**LAURUS Generics**  
Active Pharmaceutical Ingredients & Intermediates

**LAURUS Ingredients**  
Specialty Ingredients for Nutraceutical & Allied Industry

**LAURUS Synthesis**  
Contract Development & Manufacturing Services